Not satisfied with the oral JAK inhibitor Olumiant (baricitinib) as its only potential competitor for Sanofi/Regeneron Pharmaceuticals Inc.’s atopic dermatitis blockbuster Dupixent (dupilumab), Eli Lilly & Co. agreed on 10 January to pay $1.1bn in cash for Dermira Inc. and its Phase III interleukin-13 inhibitor for that indication. Lilly expects to close its acquisition of the Menlo Park, CA-based dermatology drug developer by the end of the first quarter.
Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
More from Deals
• By
The latest in a long line of restructuring moves will see Sumitomo Chemical selling its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.